Allarity Therapeutics, Inc.
ALLR
$1.52
-$0.16-9.52%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -71.41% | -17.24% | -21.66% | -21.11% | 142.46% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -4.39% | -- | -- | -- | 0.25% |
| Total Operating Expenses | -55.75% | -3.52% | 22.60% | -28.40% | 49.97% |
| Operating Income | 60.12% | 3.52% | -22.60% | 28.40% | -49.97% |
| Income Before Tax | 54.74% | 76.55% | -42.42% | 28.98% | -354.73% |
| Income Tax Expenses | -- | -- | -- | -- | -100.00% |
| Earnings from Continuing Operations | 54.74% | 75.79% | -42.42% | 28.91% | -332.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 54.74% | 75.79% | -42.42% | 28.91% | -332.81% |
| EBIT | 60.12% | 3.52% | -22.60% | 28.40% | -49.97% |
| EBITDA | 60.22% | 3.80% | -22.28% | 28.62% | -50.23% |
| EPS Basic | 87.72% | 97.53% | 95.53% | -- | -- |
| Normalized Basic EPS | 87.73% | 86.75% | 95.42% | -- | -- |
| EPS Diluted | 87.72% | 97.53% | 95.53% | -- | -- |
| Normalized Diluted EPS | 87.73% | 86.75% | 95.42% | -- | -- |
| Average Basic Shares Outstanding | 268.61% | 835.39% | 3,013.02% | -- | -- |
| Average Diluted Shares Outstanding | 268.61% | 835.39% | 3,013.02% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |